Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
If diagnosed early enough 90% of melanoma cases can be treated effectively. An exclusive study carried out by Ipsos for La Roche-Posay in 23 countries across all continents looks into the different attitudes to the sun and general knowledge of the risks associated with exposure. A massive 88% of those questioned are aware of the risks of developing skin cancer when exposed without protection to the sun. However, just 1 in 2 of those questioned have ever consulted a dermatologist for a mole screening and 1 in 4 of them have never even checked their own moles on their body.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7438251-la-roche-posay-become-skin-checker/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Clayton, one of the largest home builders in America, helped fulfill the dreams of an East Tennessee Children’s Hospital cancer patient by giving him the opportunity to design a Clayton home using CAD software commonly used at home building facilities.
Jake Clark, 16, became an honorary member of the Clayton team on Nov. 22 during a special ‘Team Jake’ celebration event at a home building facility in Bean Station, Tenn. His interests in construction projects with his dad, a home contractor, and his talents in drawing and 3D design made Jake the perfect fit to visit Clayton. While visiting the home building facility, the cancer survivor sat with a home designer and created a home model floor plan of his own, which was named “The Jake” in his honor.
To view the multimedia release go to:
https://www.multivu.com/players/English/80116510-clayton-honors-young-cancer-survivor/
The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are once again teaming up to hit home runs for prostate cancer research and encourage fans to “Keep Dad in the Game” as part of the yearly celebration of Father’s Day and annual Home Run Challenge.
This year Joe Torre, MLB’s Chief Baseball Officer, Hall of Famer and prostate cancer survivor, encourages baseball fans everywhere to support PCF’s efforts to end prostate cancer by delivering an important public service announcement, “to step up to the plate, help save lives and get one step closer to finding a cure.”
“Joe has been a great partner in our progress toward improved treatment outcomes and an eventual cure,” said PCF Founder and Chairman Mike Milken. “His work as well as those by MLB and all 30 Clubs has helped us raise more than $45 million for research programs that are saving thousands of lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7729251-pcf-and-mlb-prostate-home-run-challenge/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Supergoop!® announces its partnership with entrepreneur and international tennis sensation Maria Sharapova, welcoming her to the Supergoop! team as a co-owner with Founder and CEO Holly Thaggard. Supergoop! is the first and only multi-functional skincare line in prestige distribution with a foundation in UV protection and 100% dedication to sun safety. This partnership will be a vehicle for Supergoop! to spotlight the brand’s mission to elevate skin cancer awareness alongside the many skincare and beauty benefits attributed to applying UV protection every single day.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7190451-supergoop-partnership-tennis-maria-sharapova-sun-protection-skincare
When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Having lost his mother to the disease, singer, songwriter Gavin DeGraw knows firsthand how devastating pancreatic cancer is for patients and their families. Gavin is turning his grief into action by helping the Lustgarten Foundation raise awareness by encouraging people to get involved with the Foundation.
“My mother didn’t make it and unfortunately right now that’s a common story. But it doesn’t have to be the story permanently,” DeGraw said. “By funding research, the Lustgarten Foundation is going to change the course of this disease. I encourage everyone to get involved in some way – join a walk or make a donation.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213753-lustgarten-foundation-pancreatic-cancer-awareness/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
There is one big reason that minerals are extremely important. If certain minerals are deficient in your body then those genes that fight cancer are not activated.
Selenium is one such mineral that is necessary to activate certain genes to help you suppress the formation of cancer cells. Here is what selenium does in your body to fight cancer and improve your immune system.
